🧬 biology

Can Leukocyte Glucose Consumption Explain the HbA1c Reduction After BCG Vaccination in Long-Standing Type 1 Diabetes? A Quantitative Plausibility Analysis

This quantitative plausibility analysis concludes that increased leukocyte glucose consumption following BCG vaccination is unlikely to explain the observed HbA1c reductions in long-standing type 1 diabetes unless the entire immune system undergoes widespread reprogramming under highly permissive assumptions.

Original authors: Luis Jesuino de Oliveira Andrade, Gabriela Correia Matos de Oliveira, Osmário Jorge de Mattos Salles, Alcina Maria Vinhaes Bittencourt, Vitória Solange Coelho Ferreira, Luís Matos de Oliveira

Published 2026-10-06

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Luis Jesuino de Oliveira Andrade, Gabriela Correia Matos de Oliveira, Osmário Jorge de Mattos Salles, Alcina Maria Vinhaes Bittencourt, Vitória Solange Coelho Ferreira, Luís Matos de Oliveira

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Type 1 diabetes is a condition where the body's immune system mistakenly destroys the cells that produce insulin, leaving the blood sugar levels dangerously high. For decades, managing this disease has relied on replacing that missing insulin, but researchers have long searched for ways to help the body regulate sugar on its own or to reduce the need for external doses. One intriguing avenue of investigation involves the Bacillus Calmette-Guérin, or BCG, vaccine. Originally developed to prevent tuberculosis, this vaccine has shown unexpected side effects in some people with long-standing type 1 diabetes, leading to a significant drop in their average blood sugar levels over several years. Scientists have proposed a specific reason for this drop: they believe the vaccine reprograms the body's white blood cells, causing them to consume far more glucose than usual. If these cells are acting like a massive sponge, soaking up sugar from the bloodstream, they could theoretically explain why blood sugar levels fall without the need for extra insulin. However, for this idea to hold water, the immune system would need to be capable of consuming a staggering amount of sugar, a quantity that had never been calculated against the actual size and energy needs of the human immune system.

A team of researchers set out to test whether this biological explanation could possibly work on a large scale. They did not conduct a new clinical trial with patients; instead, they built a sophisticated computer simulation to weigh the numbers. Their goal was to compare two things: the amount of extra sugar the body would need to lose to match the improvements seen in the BCG vaccine trials, and the maximum amount of sugar the immune system could possibly consume if its cells were working at their absolute limit. The researchers started with the known results from previous studies, where patients saw their blood sugar markers drop by ten percent after three years and eighteen percent after four years. They translated these percentages into the actual amount of sugar that would need to disappear from the bloodstream every minute to cause such a change. This calculation showed that the body would need to dispose of anywhere from roughly six to nearly forty milligrams of glucose every single minute, depending on how the body's natural sugar processing works.

Next, the team estimated the capacity of the immune system to act as that sugar sink. They calculated the total weight of immune cells in an average adult and determined how much glucose those cells normally use just to stay alive. Then, they modeled what would happen if these cells were "reprogrammed" to burn sugar much faster, similar to how a car engine revs higher when pushed. They tested three different scenarios to see how much of the immune system would need to change. In the first scenario, only the T cells, a specific type of white blood cell, were reprogrammed. In the second, a broader group called the myeloid lineage was affected. In the third and most extreme scenario, the entire immune system was assumed to be reprogrammed. The simulation ran hundreds of thousands of times, mixing in different possible values for how fast cells burn sugar and how much of the immune system is actually involved, to see if the immune system's hunger for sugar could ever match the body's need to lower blood sugar.

The results of this massive calculation were revealing. When the researchers looked at the scenario where only T cells were reprogrammed, the immune system's ability to consume sugar was completely insufficient; the capacity was only about 0.6% of what was required. Even when they expanded the scenario to include the myeloid lineage, the immune system still could not consume enough sugar to explain the observed drops in blood sugar, meeting the requirement in only 5.7% of the simulations for the larger 18% reduction. The only time the numbers came close to matching was in the most extreme case, where the entire immune system was reprogrammed and the body's natural sugar processing was assumed to be very efficient. Even then, the immune system only had enough capacity to explain the sugar drop in about half of the simulations for the smaller 10% reduction, but only 28% for the larger 18% reduction. When the researchers adjusted the assumptions to be less favorable, the likelihood of the immune system being the sole cause dropped to near zero.

The study concludes that while the vaccine clearly triggers changes in how immune cells use energy, it is highly unlikely that this increased sugar consumption is the main reason blood sugar levels fall in patients. The immune system simply does not have enough mass or metabolic power to act as the primary engine for such a dramatic reduction in blood sugar. The researchers suggest that the vaccine is likely working through a more complex, indirect path, perhaps by changing how the liver or other organs handle sugar, or by altering the body's sensitivity to insulin, rather than by having white blood cells eat the sugar directly. This does not mean the vaccine is ineffective or that the biological changes are not real; it simply means that the specific idea of white blood cells acting as a giant sugar sponge is not a plausible explanation for the clinical results. The true mechanism remains a mystery, but this analysis has ruled out one popular theory, guiding future scientists to look elsewhere for the answer.

Technical Summary: Quantitative Plausibility of Leukocyte Glucose Consumption in BCG-Induced HbA1c Reduction

Problem Statement
Clinical trials involving Bacillus Calmette-Guérin (BCG) vaccination in patients with long-standing Type 1 Diabetes Mellitus (T1DM) have reported sustained reductions in glycated hemoglobin (HbA1c) of approximately 10% at year 3 and 18% at year 4. The proposed mechanism for this improvement is a systemic shift in glucose metabolism driven by increased leukocyte glucose consumption, specifically through a reprogramming of immune cells toward aerobic glycolysis (trained immunity). However, the physiological plausibility of this mechanism has not been quantitatively verified. It remains unknown whether the total glucose mass that the human immune system could theoretically consume, even under maximal reprogramming, is sufficient to account for the magnitude of whole-body glucose disposal required to lower HbA1c by the observed amounts.

Methodology
The authors conducted a quantitative plausibility analysis using a Monte Carlo bounding model to compare the "demand" for extra glucose disposal against the "capacity" of the immune system to provide it.

Demand Layer (Layer A): The model converted reported HbA1c reductions (10% and 18% from a baseline of 7.36%) into estimated mean glucose reductions using the A1C-Derived Average Glucose (ADAG) equation. The required extra glucose disposal ( $R$ ) was calculated based on whole-body glucose turnover, body weight (73 kg), and a sensitivity parameter ( $\phi$ ) representing the fraction of basal glucose disposal that is glucose-dependent. Two boundary scenarios for $\phi$ were tested: 0.3 (favorable to the hypothesis, implying low glucose-dependence) and 1.0 (unfavorable, implying all disposal is glucose-dependent).
Capacity Layer (Layer B): The model estimated the extra glucose uptake attainable by reprogrammed immune cells ( $E$ $E$ ). This calculation incorporated:
- Immune Mass: A log-normal distribution centered at 1.2 kg.
- Resting Uptake: Anchored to $^{18}$ F-fluorodeoxyglucose (FDG) PET metabolic rates.
- Metabolic Shift: A fold increase in glucose uptake per cell ( $F$ ) derived from ATP-yield stoichiometry (comparing glycolysis vs. oxidative phosphorylation) and an ATP-demand multiplier.
- Reprogramming Scenarios: Three distinct scenarios were modeled based on the fraction of immune mass ( $p$ $p$ ) affected:
  1. T cells/Regulatory T cells (Treg) only.
  2. Trained myeloid lineage.
  3. The whole immune system (a deliberate upper-bound assumption where $p=1$ ).
Simulation: 200,000 independent iterations were run for each combination of HbA1c reduction, $\phi$ value, and reprogramming scenario. The primary outcome was the capacity-to-demand ratio ( $Q = E/R$ ) and the probability of sufficiency ( $P(Q \geq 1)$ ).

Key Results
The analysis revealed that the sufficiency of leukocyte glucose consumption as a mechanism is highly dependent on the assumptions regarding the glucose-dependent share of disposal ( $\phi$ ) and the extent of immune reprogramming.

Demand Estimates: To achieve the reported reductions, the body required an extra glucose disposal of 6.5–11.6 mg/min (at $\phi=0.3$ ) and 21.5–38.8 mg/min (at $\phi=1.0$ ).
Capacity vs. Demand:
- T Cell/Treg Only: The immune capacity was negligible compared to demand. The probability of sufficiency was 0% across all scenarios.
- Trained Myeloid Lineage: Even under favorable assumptions ( $\phi=0.3$ ), the median capacity-to-demand ratio was 0.17 for an 18% reduction, with a sufficiency probability of only 5.7%.
- Whole Immune System: This scenario provided the highest capacity. At $\phi=0.3$ , the median ratio for an 18% reduction was 0.57, with a 28.2% probability of sufficiency. For a 10% reduction at $\phi=0.3$ , the median ratio exceeded 1 (1.03), with a 51.0% probability of sufficiency.
- Unfavorable Bound ( $\phi=1.0$ ): Under the assumption that all basal disposal is glucose-dependent, the probability of sufficiency dropped to near zero for all scenarios (maximum 11.2% for the whole system with a 10% reduction).
Sensitivity: The results were most sensitive to the per-cell fold increase in glucose uptake, the reprogrammed fraction, and the resting glucose uptake. Increasing the assumed resting uptake significantly improved the probability of sufficiency in the whole-immune-system scenario.

Significance and Claims
The paper concludes that increased leukocyte glucose consumption is unlikely to be the sole or dominant mechanism explaining the reported HbA1c reductions in long-standing T1DM, unless a set of highly permissive assumptions are simultaneously true: specifically, that the glucose-dependent share of basal disposal is low ( $\phi \approx 0.3$ ) and that the entire immune system (not just specific lineages) undergoes metabolic reprogramming.

The authors assert that while BCG-induced immunometabolic remodeling is biologically plausible and supported by cellular and transcriptomic data, these cellular changes should not be equated with a quantitatively sufficient systemic glucose-lowering mechanism. The study highlights a critical distinction between increased cellular glucose uptake for biosynthetic and regulatory purposes (trained immunity) and net systemic glucose clearance. The findings suggest that alternative or additional mechanisms—such as improved insulin sensitivity, reduced hepatic glucose production, or broader multifactorial interactions—must be considered to explain the clinical observations. The authors emphasize that direct metabolic studies are required to determine the actual contribution of immune-cell reprogramming to whole-body glucose disposal.

Technical Summary: Quantitative Plausibility of Leukocyte Glucose Consumption in BCG-Induced HbA1c Reduction

More like this